PI
PTGX icon

PEAK6 Investments’s Protagonist Therapeutics PTGX Stock Holding History

PEAK6 Investments’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,700
Closed -$267K – 3978
2024
Q2 		$267K Hold
7,700
– – ﹤0.01% 2613
2024
Q1 		$223K Buy
+7,700
New +$210K ﹤0.01% 3000
2023
Q2 		– Sell
-5,000
Closed -$115K – 4550
2023
Q1 		$115K Buy
+5,000
New +$84K ﹤0.01% 3445

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6 Investments's PTGX Position: Q3 2024 in Review

PEAK6 Investments held its Protagonist Therapeutics (PTGX) position steady in Q3 2024 at 13,303 shares worth $599K. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

PEAK6 Investments first reported a position in PTGX in Q1 2024 and has held it in 3 quarters since. 240 funds tracked by Wall St. Rank hold PTGX as of Q3 2024.

  • PEAK6 Investments held 13,303 shares of Protagonist Therapeutics worth $599K as of Q3 2024.
  • PEAK6 Investments left its Protagonist Therapeutics share count unchanged in Q3 2024.
  • Protagonist Therapeutics made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2212 holding.
  • PEAK6 Investments first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 240 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.